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ABSTRACT 
The human herpes virus, Epstein-Barr virus (EBV), is a known oncogenic virus 
and plays important roles in life-threatening T/NK-cell lymphoproliferative disorders 
(T/NK-cell LPD) such as hypersensitivity to mosquito bite (HMB), chronic active EBV 
infection (CAEBV), and NK/T-cell lymphoma/leukemia. During the clinical courses of 
HMB and CAEBV, patients frequently develop malignant lymphomas and the diseases 
passively progress sequentially. In the present study, gene expression of 
CD16(-)CD56(+)-, EBV(+)HMB, CAEBV, NK-lymphoma, and NK-leukemia cell lines, 
which were established from patients, was analyzed using oligonucleotide microarrays 
and compared to that of CD56brightCD16dim/-NK cells from healthy donors. Principal 
components analysis showed that CAEBV and NK-lymphoma cells were relatively 
closely located, indicating that they had similar expression profiles. Unsupervised 
hierarchal clustering analyses of microarray data and gene ontology analysis revealed 
specific gene clusters and identified several candidate genes responsible for disease that 
can be used to discriminate each category of NK-LPD and NK-cell 
lymphoma/leukemia. 
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INTRODUCTION 
The human herpes virus, Epstein-Barr virus (EBV), is a known oncogenic virus. 
EBV plays important roles in the oncogenesis of some tumors such as Burkitt’s 
lymphoma, nasopharyngeal carcinoma, and gastric cancer. Since the late 1970s, EBV 
has been thought to be associated with life-threatening T/natural killer-cell 
lymphoproliferative disorders (T/NK-cell LPD) such as hypersensitivity to mosquito 
bite (HMB), hydroa vacciniforme, chronic active EBV infection (CAEBV), and 
NK/T-cell lymphoma/leukemia [1-8]. 
  T/NK-cell LPD are often complicated with hemophagocytic syndrome and 
become fatal. Additionally, patients frequently develop malignant lymphomas during 
the clinical courses of HMB and CAEBV. Indeed, there have been some reports of fatal 
cases in which CAEBV developed from HMB and progressed to nasal NK/T-cell 
lymphoma, suggesting that T/NK-cell LPD are sequential diseases [9-13]. Difficulties 
associated with the study of EBV-associated T/NK-cell LPD include:  
1) Unknown pathogenesis; studies have shown that, in these diseases, EBV 
somehow infects T or NK cells, but the mechanism(s) of infection, and how 
EBV affects these cells as an oncogenic virus, remain unclear [1, 2, 3]. 
2) Poor prognosis; severe HMB and CAEBV are treated with 
immunosuppressant and anti-cancer drugs, but the efficacy of these drugs is 
very limited, and hematopoietic stem cell transplantation (HSCT) is the only 
curative therapy. The five-year overall survival of NK/T-cell 
lymphoma/leukemia patients ranges from 8 to 55% [11, 13, 14]. As such, the 
prognosis of EBV-associated T/NK-cell LPD is very poor. 
3) Differences in disease prevalence between areas, and rarity of the disease; 
EBV-associated T/NK-cell LPD are very rare, especially in Europe and North 
America, and they are usually observed in East Asian countries, including 
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Japan. The areas and patient numbers for these diseases are limited, which 
might explain why there are so few investigations of T/NK-cell LPD. 
  Human NK cells are divided into different subpopulations based on relative 
expression of the surface markers CD16 and CD56 [2, 6, 15]. The two major subsets are 
CD56brightCD16dim/- and CD56dimCD16+. CD56brightCD16dim/-NK cells comprise the 
majority of the NK cell population in secondary lymphoid tissues such as the lymph 
nodes, tonsils and spleen. Although they produce many cytokines, they have poor 
cytotoxic ability compared to CD56dimCD16+NK cells, which comprise the majority of 
the NK cell population in peripheral blood [2, 6, 16, 17]. 
  In the present study, we focused on EBV-associated NK-LPD using the surface 
phenotype CD56brightCD16dim/- of EBV-associated T/NK-cell LPD cell lines. Some of 
the EBV-negative T/NK-cell LPD cell lines had a CD56dimCD16+ surface phenotype. 
We compared the gene expression of the EBV-associated CD56brightCD16dim/-T/NK-cell 
LPD cell lines that we analyzed using oligonucleotide microarrays with that of control 
CD56brightCD16dim/-NK cells, which were freshly collected from the tonsils of healthy 
donors, and of peripheral blood mononuclear cells (PBMCs) from healthy volunteers. 
Several comprehensive expression analyses of CAEBV have been reported, including 
an EBV DNA microarray and an oligonucleotide DNA microarray of nasal NK/T 
lymphoma and CAEBV [18-21]. However, to the best of our knowledge, the present 
study is the first to use a microarray to investigate expression profiles of 
EBV-associated CD56brightCD16dim/-T/NK-cell LPD, including the sequential diseases of 
HMB, CAEBV, NK-lymphoma, and NK-leukemia.  
  We isolated several candidate genes responsible for disease in each step of the 
sequential disease transformation in the present gene expression profile analyses. 
 
MATERIALS AND METHODS 
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Patient Samples 
  Paraffin blocks of lymphoma samples from the archives of the Department of 
Pathology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama University, the Department of Pathology and Laboratory Medicine, Nagoya 
University Hospital, and related hospitals were used. Reactive lymphoid hyperplasia 
(RLH) and tonsils were used as normal controls. Informed consent was obtained from 
all patients for the analysis of their tissue samples. This study was approved by the 
Institutional Review Board of the Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Okayama University and related hospitals, in accordance with 
the Declaration of Helsinki. 
Cell Culture 
  Five EBV-positive NK tumor cell lines were used (Table S1). KAI3, SNK10 and 
NK-YS were established from the peripheral blood of a patient with HMB [22], with 
CAEBV [23] and with nasal NK/T lymphoma in a leukemic state [24], respectively. 
SNK6 and HANK1 were derived from the primary lesion of a nasal NK/T lymphoma 
[23, 25]. KAI3 was maintained in AIM-V (GIBCO, Grand Island, NY) supplemented 
with 10% bovine serum (Sankou Junyaku, Chiba, Japan) and 50 U/ml interleukin (IL)-2 
(Strathman Biotech GMBH, Hannover, Germany). SNK10 and SNK6 were maintained 
in Gm+RPMI (GIBCO) supplemented with 10% human serum and 700 U/ml IL-2. 
HANK1 and NK-YS were maintained in IMDM (GIBCO) supplemented with 10% 
bovine serum and 100 U/ml IL-2.  
  PBMCs were obtained from healthy donors using Ficoll-Paque Plus density gradient 
centrifugation. CD16(-)NK cells were isolated from the tonsils of healthy donors using 
the MACS CD56(+)CD16(-)NK Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). 
Microarray Analysis 
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  Total RNA was isolated from cells using the RNeasy Mini or Micro Kit (Qiagen, 
Düsseldorf, Germany), followed by DNase treatment to remove contaminating genomic 
DNA. RNA quality was verified using agarose gel electrophoresis. The ratios of the 
optical densities measured at 260 nm and 280 nm (OD260/OD280) were between 1.8 
and 2.1.  
Synthesis of cDNA, cRNA labeling, and hybridization, were performed using the 
GeneChip One-cycle Target Labeling Kit and Human Genome U133 Plus 2.0 arrays 
(Affymetrix, Santa Clara, CA, USA).  
  The Affymetrix Microarray Suite 5.0 Statistical Algorithm was used for calculation 
of the signal intensity and the detection calls for each gene. Probes associated with low 
expression, and probes classified as having absent detection calls in all samples, were 
excluded. Probe datasets were normalized through the following steps using the Subio 
Platform software (Subio, Nagoya, Japan): 1) shifting of low signals of <1.0 to 1.0; 2) 
transforming into log2; 3) applying global normalization to the 75th percentile; and then 
4) calculating ratio against the mean of PBMC1 and PBMC2. Principal Component 
Analysis (PCA) and Hierarchal Clustering Analyses (HCA) were performed using the 
differentially expressed probe sets between the six groups identified by one-way 
analysis of variance (ANOVA; p < 0.05) as previously described [26]. Differentially 
expressed genes were subjected to gene ontology (GO) analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID). Pathway-specific 
analysis was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
Pathway database.  
Immunohistochemical Staining 
  Paraffin blocks were retrieved and new CAEBV and NK lymphoma sections were 
used to ensure staining quality. Mouse monoclonal antibodies against CD56, CD3 
(NCL-CD56-1B6 and NCL-L-CD3-565, respectively; Novocastra, Newcastle upon 
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Tyne, UK) and CD16 (No.7530, Becton Dickinson, San Jose, CA, USA); rabbit 
monoclonal anti-survivin antibody (#2808, Cell Signaling Technology, Beverly, MA, 
USA); and rabbit polyclonal anti-SHP2 (GTX101062, GeneTex, San Antonio, TX, 
USA) and anti-SHP1 (sc287, Santa Cruz Biotechnology, Santa Cruz, MA, USA) 
antibodies were used. Staining was performed with a Leica BOND-MAX™ autostainer 
(Leica Biosystems, Melbourne, VIC, Australia). Both staining intensity and the 
percentage of positive tumor cells were evaluated in ten high-power fields by three 
investigators. 
Fluorescent immunohistochemical staining 
 The procedure was as described previously [27]. Rabbit monoclonal anti-Fas  
(ab133619, Abcam, MA, USA), mouse monoclonal anti-CD56, anti-mouse IgG Alexa 
Flour 555 and anti-rabbit IgG Alexa Flour 488 (Invitrogen, Oregon, USA) antibodies 
were used for this analysis. 
Western blotting analysis 
Western blot analyses of the cell lines were performed as described previously  
[28]. Antibodies used for these analyses were: anti-SHP1, anti-SHP2 and anti-survivin 
antibodies as described for immunohistochemical staining, and rabbit monoclonal 
anti-Cyclin D1, anti-Cyclin A2 (#2978 and #4656 respectively, Cell Signaling, Beverly, 
MA, USA), anti-Cyclin E2 (ab40890, Abcam) and anti-Fas (ab133619, Abcam) 
antibody; mouse anti-beta-actin (A5441, Sigma Aldrich, St. Louis, USA) antibody; and 
HRP-labeled anti-rabbit or anti-mouse (NA9340 and NA9310, respectively, GE 
Healthcare, Little Chalfont, Buckinghamshire, UK) antibodies. 
Flow cytometric (FCM) analysis of the cell cycle  
  Cells were stained with propidium iodide (PI), and the cell cycle was analyzed using 
the FACS Calibur (BD BioScience, CA, USA) as described previously [29]. 
RESULTS 
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Principal Component Analysis and Unsupervised Hierarchal Clustering Analyses. 
  PCA of gene expression indicated some distance between three groups of cells; 1) 
normal PBMCs, 2) NK-type cells including normal CD16(-)NK cells, HMB, CAEBV  
and NK-lymphoma, and 3) NK-leukemia, according to the first two principal 
components (Figure 1A). PCA analysis of the NK-type cells showed that normal 
CD16(-)NK cells are distantly related to NK-LPD cells. NK-LPD cells are subdivided 
into three categories: 1) HMB, 2) CAEBV and NK-lymphoma, and 3) NK-leukemia. 
The first two principal components explained 44.4% of the variance. CAEBV and 
NK-lymphoma cells were relatively closely located on the scatterplot, indicating that 
they had similar expression profiles (Figure 1B). 
  HCA identified seven gene clusters according to characteristic gene expression 
patterns: Cluster A-1 showed downregulation and Cluster A-2 showed upregulation in 
HMB, CAEBV, NK-lymphoma and NK-leukemia versus normal NK cells; Cluster B-1 
showed downregulation and Cluster B-2 showed upregulation in CAEBV, 
NK-lymphoma and NK-leukemia versus normal NK cells and HMB; Cluster C showed 
downregulation in NK-lymphoma and NK-leukemia versus normal NK cells, HMB and 
CAEBV. Cluster D-1 showed downregulation and Cluster D-2 showed upregulation in 
NK leukemia versus normal NK cells, HMB, CAEBV and NK-lymphoma; Clusters B, 
C and D showed differential expression profiles among each node of HMB, CAEBV, 
NK-lymphoma and NK-leukemia that discriminated each disease (Figure 1C, Table S2, 
S3, S4, S5, S6, S7, S8). 
Gene Ontology (GO) Analyses of Differentially Expressed Genes. 
  GO analysis indicated significantly enriched GO categories in biological processes 
for each differentially expressed cluster; the top seven enriched GO term categories for 
each cluster are summarized in Table I. 
  Genes in Cluster A-1 shared common GO terms related to the “Src-homology-3 
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domain”, “Immunoglobulin subtype”, “Cytoskeleton”, “Neutrophin signaling pathway”, 
“Circadian rhythm” and “Regulation of transcription”. Representative genes included 
GPR82, MYO18B, CYP1B1, S100A8, HBA1 &2, NRGN, NR4A2, PTPN6, HBB, CD6, 
LYZ, PPBP, RNF130, KLF4, RASA3 and LY9. 
  Cluster A-2 was enriched for GO term categories such as “Membrane-encoded 
lumen”, “DNA replication and DNA metabolic process”, “RNA binding and RNA 
processing” and “Cell cycle and cell division”, and included RFC2, PTP4A1, JAK3, 
STAT3, CISH(CIS), DHFR, FOXM1, CDC45L, CXCL10, FDXR, PTPN11, BIRC5, 
DHRS2, GEMIN4 and GINS3. Cluster B-1 was enriched for GO term categories such as 
“Lymphocyte mediated immunity”, “Membrane”, “Disulfide bond”, “Phosphorus 
metabolic process” and “Regulation of apoptosis”, and included PRKCD, B4GALT6, 
LGR4, MXRA7, MYOF, PTPRN2, SEPT9, AKT3, SHC4, CRTAM, CADM1 and OSMR. 
“Regulation of apoptosis” included CADM1, CRTAM and PROK2. Genes in Cluster B-2 
shared common GO terms related to the “Endoplasmic reticulum”, “Intracellular 
signaling cascade”, “Membrane fraction”, “Phosphate metabolic process” and “Ion 
transport” and included TNFRSF10A, CCDC125, NHEDC2, CCND2, FADS2, PDGFRA, 
RCAN2, FADS1, HGF, UTP18 and ATL3. 
  Cluster C was enriched for GO term categories such as “Regulation of transcription”, 
“C2 membrane targeting protein”, “Oxidation reduction” and “Regulation of 
Wnt-receptor signaling pathway”, and included TC2N, SNX20, ZNF569, DDX3Y, 
PALLD, SOX4, TJP2, DHRS3, PHACTR2, CRY1, SEMA4A, LEF1, GPD2, SYTL1 and 
PTPLAD2. “Oxidation reduction” included RFESD, ALKBH3, DHRS3, GPD2, IDG2 
and NPHP3. “Regulation of Wnt receptor signaling pathway” included SOX4, ADCY9, 
CTNNBIP1, KLRB1, LEF1, IPAR6 and USP9Y. 
  Cluster D-1 was enriched for GO term categories such as “MHC-II protein complex 
or Cell adhesion molecules (CAMs)”, “Transmembrane”, “Negative regulation of 
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biosynthetic process”, “Transcription repressor activity” and “Negative regulation of 
RNA metabolic process”, and included CCDC141, SLC35E4, TMEM189, HLA-DPB1, 
PEPD, GNAQ, SLC16A3, BIN1, NINJ1, MYO6, BCL6, ATXN1, CRIP1, HLADRB4, 
TP63, ICOS, HLADRA, RHOB and FUNDC1. Some genes in Cluster D-1 were 
categorized in “MHC-II complex or Cell adhesion molecules (CAMs)”, including CD2, 
ICOS, ITGB7, HLA-DMA, HLA-DOA, HLA-DPA1, HLA-DQA1 and HLA-DRA.  
  Cluster D-2 shared common GO terms related to “Proto-oncogene”, “Pathway of 
cancer”, “Embryonic morphogenesis”, “Positive regulation of growth” and “Adhesion 
junction”, and included ATAD3A, NOX5, SNTG2, LOC643201, TJP1, SSX1, SSX2, 
SSX3, SPANXB1, MECOM, SPANXA2 and NEFH. “Pathway in cancer” included ITGA6, 
SPHK1, SFN, TJP1, FGF9 and TMP3. “Proto-oncogene or Regulation of transcription” 
included CSF1R, MECOM, SSX1, SSX2, SSX2B, SSX5 TIMP3 and ZNF320. 
Pathway Analysis 
  The clusters extracted from HCA were applied to pathway analysis. Some pathways 
in which several genes showed altered expression patterns were extracted. 
Cell cycle pathway 
  Many genes belonging to Cluster A-2 appear in the cell cycle pathway (Figure 2A,B). 
The expression levels of genes that promote cell cycle progression such as CDKs 
(CDK8, CDK2, BCCIP, and CDKN2AIP), cyclins (CCNA2 (CycA), CCNE2 (CycE), 
CCNB1 (CycB), and CCND2 (CycD)), a CDK substrate (NUCKS1), and SKP2, 
MCM3/4/5, MYC, MAX, MINA, CDC42, CDC42SE1, CDC23, CDC6 and CDC45L 
increased as disease progressed. Genes involved in DNA mismatch repair (MLH1, 
MSH6, EXO1, RPA3, and LIG1) and cell cycle arrest, such as genes in the P53 signaling 
pathway (TP53, TP53BP2, TRIAP1, MDM2, CDKN1A (p21/Cip1), CASP3, FAS, BAX, 
and CHK1/2), showed the same expression pattern as the cell cycle progression genes. 
Apoptosis 
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  Both apoptosis-inducing and -evading gene transcription was increased in 
EBV-positive NK-LPD (Figure S1). The transcription of pro-apoptotic genes in the 
death-signaling pathway (TNFSF10 (TRAIL), TNFRSF10B (TRAILR), TNFRSF8, 
IRAK1, IKIP, BAX, CASP3 and FAS) was increased; these genes were categorized in 
Cluster A-2. TNFSF10 (TRAIL), TNFRSF10B (TRAILR), IRAK1, IKIP, and BAX 
transcription was highest in HMB and/or CAEBV, and was decreased in EBV-positive 
NK-leukemia. Some apoptosis-evading genes, such as BCL2L1 (BCLXL), BCL2L12, 
XIAP and BIRC5 (survivin), were strongly expressed in EBV-positive NK-LPD versus 
normal NK cells. The expression levels of TNFRSF8 and BIRC5 increased as disease 
progressed. 
JAK/STAT pathway 
  In the JAK/STAT pathway, the transcription levels of JAK3 and STAT3 were increased 
in EBV-positive NK-LPD versus normal NK cells (Figure 2C,D). CSF2RB and IL-21R, 
genes that encode cytokine receptors upstream of the JAK/STAT pathway, and CIS, 
NRAS, SOCS3 and Pim-1, genes that encode downstream molecules of this pathway, 
showed the same expression pattern as that of JAK3 and STAT3, suggesting that 
enhancement of this signaling pathway may induce cell proliferation. Many related 
genes were categorized in Cluster A-2. In EBV-positive NK-LPD, expression of the 
gene PTPN6 that encodes SHP1, a negative regulator of the JAK/STAT pathway, was 
decreased, whereas expression of the gene PTPN11 that encodes SHP2, a positive 
regulator of this pathway, was strongly increased. 
Western blotting analysis 
  Western blotting analysis of the five cell lines indicated that Cyclin-D1, -E2, -A2 and 
SHP2 protein expression gradually increased, whereas SHP1 protein expression 
gradually decreased, with disease progression. Fas protein expression was strongest in 
CAEBV (SNK10) cells. Survivin protein expression was highest in NK-lymphoma 
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(HANK1, SNK6) cells (Figure 3A). 
Effects of culture medium components on protein expression and the cell cycle 
  The effects of the different culture media used for culture of the five cell lines on the 
cell cycle and related gene expression were investigated. Western blotting and cell cycle 
analyses showed that differences between the effects of the different culture media on 
cell cycle and Cyclin-D1 expression were much smaller than the changes in these 
parameters among the cell lines (Figure S2 & Table S9). 
Immunohistochemical analysis 
 Patient specimens of NK/T-lymphoma, CAEBV and RLH were 
immunohistochemically stained for protein expression of SHP-1, SHP-2, and survivin, 
which are encoded by PTPN6, PTPN11 and BIRC5, respectively (Figure 3B, Table II). 
SHP-1 staining was positive in both normal NK (72%) and T (98%) cells in RLH, and 
the strength and percentage of SHP-1 staining was lower in NK/T-lymphoma (20.0% 
SHP-1 positive), and in NK- or T-cell-type CAEBV (0% and 40.0% SHP-1 positive, 
respectively). On the other hand, SHP-2 staining was negative in both normal NK 
(3.5%) and T (2.3%) cells in RLH, whereas the strength and percentage of SHP-2 
staining gradually increased from NK- to T-cell-type CAEBV, to NK/T-lymphoma 
(28.6%, 40.0% and 60.0% SHP-2 positive, respectively). Survivin staining was faintly 
positive in both normal NK (6%) and T (1.3%) cells in RLH, and the strength and 
percentage of survivin staining was much higher in NK- or T-cell-type CAEBV (85.7% 
and 100% survivin positive respectively) and in NK/T-lymphoma (80.0% survivin 
positive). Fas staining was positive in NK-type CAEBV (71.4%) and that was lower in 
NK/T-lymphoma (20.0%) and normal NK cells in RLH (5.0%). 
DISCUSSION 
 PCA showed that the distance between CD56(+)CAEBV and NK-lymphoma cells in 
the first two principal components was very small, indicating that CD56(+)CAEBV and 
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NK-lymphoma have a closely related expression profile (Figure 1). However, 
unsupervised HCA and GO analysis indicated differential expression patterns of some 
of the specific genes in Clusters B-1 and C between these cells. Thus, several candidate 
genes responsible for disease were identified (Table I, S4 and S6) that may discriminate 
two categories of disease as well as predict clinical outcome.  
  NK-lymphoma/leukemia showed increased expression of genes involved in cell cycle 
progression, such as CDKs, cyclins, and a CDK substrate, with disease progression 
(Figure 2A,B). The anti-apoptotic genes BIRC5 (survivin) and BCL-XL, were strongly 
expressed, especially in NK-lymphoma/leukemia, indicating that 
NK-lymphoma/leukemia have more severe malignant characteristics than the other cell 
lines. In contrast, EBV-positive HMB and/or CAEBV showed gene expression patterns 
characteristic of both infection, e.g., expression of genes involved in cell cycle arrest to 
allow virus replication, and also of malignancy e.g., expression of genes involved in 
enhancement of cell cycle progression and in anti-apoptosis leading to uncontrolled cell 
proliferation. Transcription of pro-apoptotic genes in the death-signaling pathway 
(TNFSF10 (TRAIL), TNFRSF10B (TRAILR), BAX and FAS) were highest in HMB 
and/or CAEBV, indicating that HMB and/or CAEBV are competent to induce apoptosis 
and that they are intermediate diseases between premalignant and malignant (Figure 
S1,3A). This conclusion is consistent with the proposal of Oshima et al. [1] that 
CAEBV is pathologically categorized as a continuous spectrum ranging from a 
smoldering phase to overt leukemia/lymphoma. These gene expression patterns are 
consistent with the clinical features of EBV-positive NK-LPD, such as viral genome 
increases in peripheral blood or the sequential progression of disease [9-13]. 
  The expression patterns of some genes involved in the JAK/STAT pathway were 
altered in EBV-positive NK-LPD, especially of PTPN6 (SHP1) and PTPN11 (SHP2), 
which encode non-receptor type protein tyrosine phosphatases that are reported to be 
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involved in some malignant diseases [28,30-36]. SHP1 is a negative-regulator of 
JAK/STAT signaling [28,30,31]. Decreased expression of SHP1 in HMB (KAI3) cells 
may be responsible for the hypersensitivity to mosquito bite and prolonged 
inflammation. Downregulation of PTPN6 gene expression by CpG-island DNA 
hypermethylation and the loss of heterozygosity are frequently observed in many 
lymphomas/leukemias [28,30-35]. PTPN11 was isolated as the gene whose germline 
mutation is responsible for Noonan syndrome [37]. Somatic mutations in PTPN11 
upregulate SHP2 expression and result in juvenile myelomonocytic leukemia, 
myelodysplastic syndrome or acute myeloid leukemia in pediatric patients and in gastric 
cancer with CagA-positive Helicobacter pylori infection [38-40]. SHP2 is implicated in 
multiple cell signaling pathways such as the Ras/MAPK, JAK/STAT, PI3K-AKT, NFkB, 
and NAFT pathways [39,41]. In the present study, the gene expression profiles of 
EBV-positive NK-LPD cell lines revealed suppression of PTPN6 but significantly 
increased PTPN11 expression even in HMB early stage cells versus normal NK cells, 
which were confirmed by Western blotting analysis. These evidences suggest that SHP1 
suppression and SHP2 overexpression are a key event in the tumorigenesis of 
EBV-positive NK-LPD, similar to the mechanism of H pylori(+), EBV(+) gastric cancer 
[42]. 
  Finally, we propose a hypothetical scheme for the mechanism of EBV-positive 
NK-LPD onset as follows (Figure 4). After EBV infection, SHP1 and SHP2 expression 
dramatically changes, which might affect the JAK/STAT and RAS/MAPK pathways, 
leading to abnormal proliferation. The increased expression of cyclins and CDKs may 
enhance these events. Viral genes, such as LMP1 and ZEBRA, also affect the cell cycle 
and increase the expression of DNA checkpoint genes, such as p21, p53 and chk1/2, for 
virus replication [17,43,44]. However, HMB and CAEBV still display some 
characteristics of normal cells and the expression of pro-apoptotic genes is increased in 
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these diseases versus normal NK cells. As progression to NK-lymphoma/leukemia, 
pro-apoptotic gene expression is reduced and the expression of anti-apoptotic genes 
increase. These characteristic expression pattern changes correspond to the typical 
clinical course of EBV-positive NK-LPD; NK-LPD sometimes onsets as HMB and 
progresses to CAEBV, then to NK-lymphoma, and ultimately to NK-leukemia.  
    EBV-positive NK-LPDs diseases are only observed in East Asian countries and the 
mechanisms underlying disease onset and progression remain to be elucidated. The 
prognosis of these diseases is not good. Over the long clinical course of CAEBV, almost 
all patients encounter severe complications such as hemophagocytic syndrome, 
myocarditis, NK-lymphoma or NK-leukemia, which worsen if not given HSCT with 
high-dose chemotherapy. In NK-lymphoma, the novel and most promising 
chemotherapy SMLE can achieve complete remission in only 50% of patients [44]. The 
present study revealed several gene clusters, key molecules and relevant pathways that 
are related to the tumorigenesis or progression of EBV-positive NK-LPD. These 
findings provide important information for understanding the molecular mechanisms 
underlying the sequential transformation caused by EBV infection in EBV-associated 
NK-LPD, and may also contribute to the development of new therapeutic strategies for 
these fatal diseases. 
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Figure legends  
Figure 1. Principal component analysis (PCA) of the gene expression in HMB, 
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CAEBV, NK/T-lymphoma and NK/T-leukemia cell lines, CD16(-)normal NK cells and 
healthy PBMCs. A) There is some distance between three groups, 1) healthy PBMCs, 
2) NK-type cells, including normal CD16(-)NK cells, HMB, CAEBV and 
NK-lymphoma, and 3) NK-leukemia, according to the first two principal components, 
indicating that HMB, CAEBV and NK-lymphoma cell lines retain normal CD16(-)NK 
cell characters. B) PCA analysis of NK-type cells showing that normal CD16(-)NK cells 
are distantly related to NK-LPD cells. NK-LPD cells are subdivided into three 
categories: 1) HMB, 2) CAEBV and NK-lymphoma, and 3) NK-leukemia. CAEBV 
cells show a close relation to NK-lymphoma cells. Hierarchical clustering analysis 
(HCA) of the gene expression in HMB, CAEBV, NK/T-lymphoma and NK/T-leukemia 
cell lines, CD16(-)normal NK cells and healthy PBMCs. C-I)  Clusters were 
classified into seven categories according to characteristic expression patterns. C-II) 
Cluster A-1 shows downregulation and A-2 shows upregulation in HMB, CAEBV, 
NK-lymphoma and NK-leukemia when compared to normal NK cells. Cluster B-1 
shows downregulation and B-2 shows upregulation in CAEBV, NK-lymphoma and 
NK-leukemia when compared to normal NK cells and HMB. Cluster C shows 
downregulation in NK-lymphoma and NK-leukemia when compared to normal NK 
cells, HMB and CAEBV. Cluster D-1 shows downregulation and D-2 shows 
upregulation in NK-leukemia when compared to normal NK cells, HMB, CAEBV and 
NK-lymphoma. 
Figure 2. KEGG pathway analysis of the cell cycle. A) Gene expression changes 
among cell lines and normal NK cells were mapped on to the cell cycle pathway. The 
colored boxes indicate significant upregulation (red) or downregulation (blue) of 
transcripts in normal PBMCs, normal NK cells, HMB, CAEBV, NK-lymphoma and 
NK-leukemia. B) The graphs show the mRNA expression levels of representative genes. 
Many genes belonging to Cluster A in Figure 1 C-II appear in the cell cycle pathway. 
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The expression levels of cell cycle progression genes, such as for CDKs and cyclins, 
increase with disease progression. Genes involved in DNA damage checkpoints and cell 
cycle arrest, such as p53, p21 and Chk1/2, show the same expression pattern as cell 
cycle progression genes. KEGG pathway analysis of JAK/STAT signaling. C) Gene 
expression changes among cell lines and normal NK cells were mapped on the 
JAK/STAT signaling pathway. The colored boxes indicate significant upregulation (red) 
or downregulation (blue) of transcripts in normal PBMCs, normal NK cells, HMB, 
CAEBV, NK-lymphoma and NK-leukemia. D) The graphs show the mRNA expression 
levels of representative genes. The expression levels of JAK3 and STAT3 are increased 
in EBV-positive NK-LPD, and the cytokine receptors upstream of JAK/STAT show the 
same expression pattern as JAK3/STAT3. SHP-1 expression is decreased and SHP-2 
expression is remarkably increased in EBV-positive NK-LPD. 
Figure 3. Western blot analyses of Cyclin-D1, -E2, -A2, Fas, Survivin, SHP1 and 
SHP2 in EBV(+)LPD, EBV(+)NK lymphoma/leukemia cell line and control cells. 
A) Expression of Cyclin-D1, -E2, -A2 and SHP2 was gradually increased according to 
the progression of diseases in contrast to almost no expression in normal control of 
healthy PBMCs and healthy CD16(-)NK cells. Positive control of HeLa cells, a cervical 
cancer cell line, showed positive for these proteins. Fas showed high expression in 
CAEBV (SNK10) cells and gradually decreased in NK lymphoma/leukemia cells 
(HANK1, SNK6 & NK-YS) and showed no expression in normal PBMCs and 
CD16(-)NK cells. Survivin showed highest expression in NK lymphoma cells (HANK1 
& SNK6). In contrast, SHP1 showed high expression in normal PBMCs and 
CD16(-)NK cells, gradually decreased from CAEBV, NK lymphoma to NK leukemia 
cells. HMB cell line (KAI3) showed no expression of SHP1. Immunohistochemical 
staining of SHP-2 and Survivin and immunofluorescent double staining of Fas in 
RLH, CAEBV and NK/T lymphoma. B) Representative data of Immunohistochemical 
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staining of SHP-2 and Survivin were shown. The staining of SHP-2 was negative in a) 
CD56(+)normal NK cells, but positive in both b) CD56(+)CAEBV and c) 
CD56(+)NK/T-lymphoma. The staining of survivin is very faint in d) CD56(+)normal 
NK cells, and positive in e) CD56(+)CAEBV and f) CD56(+)NK/T-lymphoma. 
(Magnification ×400; Red color: CD56; Brown color: SHP2 and survivin).  
Figure 4. Hypothetical mechanism underlying the onset of EBV-positive NK-LPD. 
After EBV infection, LMP1 or ZEBRA is expressed in the infected cells, resulting in an 
increase in ZEBRA-dependent DNA checkpoint genes, such as p21 and p53, and cell 
cycle arrest to allow virus replication. LMP1 activates the MAPK and/or NFkB pathway 
and induces c-myc expression, eventually promoting cell cycle progression and 
suppressing apoptosis. Strong repression of SHP1 expression induces the continuous 
activation of the JAK/STAT and RAS/MAPK pathways, which leads to aberrant cell 
proliferation. The increased expression of SHP2 in NK-LPD may also activate the 
RAS/MAPK pathway. Increased survivin expression in NK leukemia may suppress 
CASPA9, leading to resistance against apoptosis. 
 
A List of Supporting Information 
Table S1. Origin and characters of cell lines and normal CD16(-) NK cells. 
Table S2. Cluster A-1, which shows down regulation in HMB, CAEBV, NK lymphoma 
and NK leukemia compared to Norm NK. 
Table S3. Cluster A-2, which shows up regulation in HMB, CAEBV, NK lymphoma 
and NK leukemia compared to Norm NK. 
Table S4. Cluster B-1, which shows down regulation in CAEBV, NK lymphoma and 
NK leukemia compared to Norm NK/HMB. 
Table S5. Cluster B-2, which shows up regulation in CAEBV, NK lymphoma and NK 
leukemia compared to Norm NK and HMB. 
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Table S6.  Cluster C, which shows down regulation in NK lymphoma and NK 
leukemia compared to Norm NK, HMB and CAEBV. 
Table S7. Cluster D-1, which shows down regulation in NK leukemia compared to 
Norm NK. HMB, CAEBV and NK lymphoma. 
Table S8. Cluster D-2, which shows up regulation in NK leukemia compared to Norm 
NK, HMB, CAEBV and NK lymphoma. 
Table S9, Cell cycle analysis of NK cell lines in the different medium condition. 
 
Figure S1. KEGG pathway analysis of apoptosis. A) Gene expression changes among 
cell lines and normal NK cells were mapped on the apoptotic pathway. The colored 
boxes indicate significant upregulation (red) or downregulation (blue) of transcripts in 
normal PBMCs, normal NK cells, HMB, CAEBV, NK-lymphoma and NK-leukemia. B) 
The graphs show the mRNA expression levels of representative genes. The expression 
levels of both apoptosis-inducing and -evading genes are increased in EBV-positive 
NK-LPD. 
Figure S2. Effects of culture medium condition on cyclin-D1 expression. A) In order 
to investigate the effects of culture medium condition on the expression of cell cycle 
related genes, Western blot analyses of Cyclin-D1 was performed. Cyclin–D1 
expression showed gradually increased from KAI3, SNK10, HANK1, SNK6 and NKYS 
as disease progression in contrast to no expression in normal controls. B) On the other 
hand, Cyclin-D1 expression showed almost no difference in the different culture 
condition of each cell line, indicating that different medium condition induced almost 
no effects on Cyclin-D1 expression. Medium1: Gm+RPMI supplemented with 10% 
human serum and 700 U/ml IL-2, Medium2: AIM-V supplemented with 10% bovine 
serum and 50 U/ml IL-2, Medium3: IMDM supplemented with 10% bovine serum and 
100 U/ml IL-2.  
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Figure S3. Effects of culture medium condition on cell cycle. In order to investigate 
the effects of culture medium condition on cell cycles of each cell line, Flow cytometry 
(FCM) analyses were performed, showing that the difference of medium condition does 
not affect so much on cell cycle in each cell line in contrast to the large difference 
among cell lines. Detailed data of cell cycle states were summarized in Table S9. 
Figure S4 Immunofluorescent double staining of Fas and CD56 in RLH, CAEBV and 
NK/T lymphoma. a) RLH patient specimen was treated with rabbit anti-Fas and, b) 
mouse anti-CD56 antibodies followed by anti-rabbit IgG Alexa488 (green) and 
anti-mouse IgG Alexa555 (red) and c) stained with DAPI (blue). d) Images of a), b), 
and c) were merged. No CD56(+)NK cells showed Fas-positive in RLH. e) CAEBV 
patient specimen was treated with rabbit anti-Fas antibody, f) mouse anti-CD56 
antibody followed by second antibodies staining as in RLH and g) stained with DAPI. 
h) Images of e), f), and g) were merged. CD56(+)NK cells in CAEBV showed 
Fas-positive (arrows). i) NK/T lymphoma patient specimen was treated with rabbit 
anti-Fas antibody, j) mouse anti-CD56 antibody followed by second antibodies staining 
and k) stained with DAPI. l) Images of i), j), and k) were merged. No CD56(+)NK cells 
showed Fas-positive in NK/T lymphoma ( bar indicates 20 micron) 
 
Supplemental information 
Supplemental explanation about microarray analysis methods specifically about 1) 
why were low signals transformed to 1.0 instead of eliminated? 2) Why was global 
normalization chosen to the 75th percentile rather than to housekeeping genes, 
which would better account for both cell sample and cDNA quality?   
1) This analysis method has been used in many articles in the field of microarray. 
The reason why low signals transformed to 1.0 instead of eliminated, is data was 
normalized with 75th percentile later and this transformation will affect to these 
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process. The 75th percentile is reasonable to be 75th percentile of all measured 
values. If low signals are eliminated, data will shift from 75th percentile. The total 
number of probe sets, showing less than 1.0, is different among each array. The 
75th percentile becomes different among arrays if low signals are eliminated. 
Additionally, low signals are eliminated in the filtering process in later, so we do 
not need to eliminate low signals in this step. For example, the expression pattern 
such as 0.1, 100, 20 is better to transform to 1, 100, 20, because in the case of NA 
(eliminated value is transformed to Not Applicable), 100, 20 become impossible 
to compare the values between 1st and 2nd values, or 1st and 3rd values.   
2) The global normalization has been accepted to be better than the normalization 
with housekeeping genes in the case of genome wide analyses.  
     
Why was one-way ANOVA used to generate the list from the probe-set instead 
of two-way? 
   The reason why we chose one-way ANOVA, is that the parameter is only one. 
One-way ANOVA is appropriate in the case of one-dimensional analysis. 
 
 
 
 
 
 
 
